ロード中...

Alemtuzumab Therapy for Multiple Sclerosis

Alemtuzumab is a humanized monoclonal antibody that is administered daily for 5 days, and then no further therapy is required for 12 months. It causes rapid and prolonged lymphocyte depletion; the consequent homeostatic reconstitution leads to a radically reformed lymphocyte pool with a relative inc...

詳細記述

保存先:
書誌詳細
第一著者: Coles, Alasdair J.
フォーマット: Artigo
言語:Inglês
出版事項: Springer-Verlag 2012
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3557360/
https://ncbi.nlm.nih.gov/pubmed/23184314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13311-012-0159-0
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!